CCDS Research Paper Repository & Summaries

ACD Summary: Sun et al. screened for the presence of a CCDS in 3,586 patients who exhibited a developmental delay. Screening involved measuring creatine and guanidinoacetate (GAA) levels in blood, creatine:creatinine levels in urine, and creatine signals in the brain. In total, 14 patients had a confirmed CCDS (6 with GAMT deficiency, 8 with CTD). There were also brain structural differences in some of the patients. In patients with GAMT deficiency, treatment involved a low-protein diet and supplementation with creatine and ornithine. After 2 to 3 weeks of treatment, creatine and GAA levels in blood returned to a normal range; after 6 to 9 months, their brain’s creatine signals increased dramatically. In 3 patients with GAMT deficiency, epilepsy was resolved after 3 to 6 months of treatment. Overall, treatment was associated with a general improvement in the children with GAMT deficiency. For patients with CTD, there was minimal (if any) improvement given supplementation treatment with creatine, glycine, and/or arginine. In conclusion, the authors recommended that patients with a developmental delay, feeding or growth difficulties, and epilepsy should be screened for CCDS.

Link to free article on PubMed: Fourteen cases of cerebral creatine deficiency syndrome in children: a cohort study in China

ACD Summary: Tise et al. described a 20-month-old boy with CTD, diagnosed via urine analyses, genetic testing (which revealed a novel SLC6A8 variant), and magnetic resonance spectroscopy (a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues). The patient began a program of creatine, arginine, and glycine supplementation. At 40 months old (~1 year after starting the supplementation program), the patient showed improved development and weight gain; the authors described the patient as “active and playful… currently no longer requiring or receiving physical or occupational therapy”. Despite limited verbal communication, the patient is able to sign and express his wants and needs, also showing evidence of language comprehension. The authors suggested that this novel SLC6A8 variant may be more receptive to therapy. The authors further emphasized the need for enhanced newborn screening programs and suggest that CTD should be considered in patients showing developmental delays.

Link to free article: Creatine Transporter Deficiency Presenting as Failure to Thrive: A Case Report of a Novel SLC6A8 Variant Causing a Treatable but Likely Underdiagnosed Genetic Disorder

Link to PubMed: PubMed

ACD Summary: Rosko et al. used mouse models of GAMT deficiency to better understand creatine production in the central nervous system (which refers to the brain and spinal cord). Animal models are ultimately helpful for humans because researchers can perform experiments with animals that they would not be ethically allowed to do with people. These authors showed that the main source of the brain’s ability to make creatine is within types of brain cells called oligodendrocytes (pronounced “uh-leh-go-DEN-dro-sites”). These types of cells are responsible for building structures that wrap around nerve cells so that different parts of the brain can work together more efficiently; these structures, called myelin (pronounced “MY-eh-lin”), prevent brain activity from getting lost, like how coats wrapped around our bodies prevent our body heat from escaping. When GAMT was not expressed in these mouse brains, there was a delay in the brain’s ability to create myelin. However, dietary supplementation of creatine did help restart this process of creating myelin. In conclusion, these authors suggest that oligodendrocyte function may be an important mechanism in CCDS.

Link to free article: Cerebral Creatine Deficiency Affects the Timing of Oligodendrocyte Myelination

Link to PubMed: PubMed

ACD Summary: Mabondzo et al. used a mouse model of CTD to better understand (1) which proteins are related to CTD and (2) whether treatment with dodecyl creatine ester (DCE changes the amount of those proteins in the brain. (In March 2021, DCE was suggested to the FDA as a possible treatment for CTD, but it has not yet been approved by the FDA for this purpose.) DCE was given through the nose to a group of mice that did not express the SLC6A8 gene (which needs to be expressed for creatine transport to happen); mice that do not express (or have mutations in) the SLC6A8 gene are called “SLC6A8 knockout” mice. SLC6A8 knockout mice given DCE showed significant improvements in cognition, similar to the mice that did express SLC6A8. In the brains of these same mice, the authors identified 14 different proteins that were altered by SLC6A8 expression and by being given DCE. (Interestingly, 13 of these 14 proteins have been shown to be related to other disorders characterized by intellectual disability, such as autism). For example, in the SLC6A8 knockout mice, there was a large amount of the KIF1A protein, and the mice that showed a greater amount of this protein showed lower cognition. These results suggest that K1F1A (as well as another protein, PLCB1) may be an important mechanism related to CTD and that treatment with DCE may help restore cognitive deficits of CTD.

Link to free article: Dodecyl creatine ester improves cognitive function and identifies key protein drivers including KIF1A and PLCB1 in a mouse model of creatine transporter deficiency

Link to PubMed: PubMed

ACD Summary: Mustafa et al. analyzed levels of guanidinoacetic acid (GAA), creatine, and creatinine in urine in neurotypical children ages 0- to 15-years-old in Egypt. Specifically, the authors looked at the ratio of GAA to creatinine (GAA:creatinine) and the ratio of creatine to creatinine (creatine:creatinine). Typically, GAA:creatinine levels in urine are low in patients with AGAT deficiency, elevated in patients with GAMT deficiency, and normal in patients with CTD. In contrast, creatine:creatinine levels in urine are normal in patients with AGAT or GAMT deficiency and may be elevated in patients with CTD. These ratios are used by physicians to help with diagnosing CCDS. Accordingly, Mustafa et al. wanted to determine how these ratio levels change with age, so they could begin to establish an age-specific reference level for these diagnostic criteria. The authors collected data on 160 children but removed 10 children from analysis because of positive screening for a CCDS. For the remaining 150 neurotypical children, there was a steady decline in GAA:creatinine and creatine:creatinine levels with age, with there being a large difference in these average levels when comparing children less than 4 years old to children between 4 and 15 years old. Accordingly, the reference criteria for diagnosing CCDS may change with age at time of diagnosis, which may be contributing to the underdiagnosis of CCDS.

Link to free article: Age Adjusted Reference Interval for Creatine Deficiency Syndrome Biomarkers by Gas chromatography-Mass Spectrometry

Scientific Abstract: Creatine deficiency syndromes (CDS) are inherited metabolic disorders caused by mutations in GATM, GAMT and SLC6A8 and mainly affect central nervous system (CNS). AGAT- and GAMT-deficient patients lack the functional brain endogenous creatine (Cr) synthesis pathway but express the Cr transporter SLC6A8 at blood-brain barrier (BBB), and can thus be treated by oral supplementation of high doses of Cr. For Cr transporter deficiency (SLC6A8 deficiency or CTD), current treatment strategies benefit one-third of patients. However, as their phenotype is not completely reversed, and for the other two-thirds of CTD patients, the development of novel more effective therapies is needed. This article aims to review the current knowledge on Cr metabolism and CDS clinical aspects, highlighting their current treatment possibilities and the most recent research perspectives on CDS potential therapeutics designed, in particular, to bring new options for the treatment of CTD.

Link to free article: Current and potential new treatment strategies for creatine deficiency syndromes

Link to PubMed: PubMed

ACD Summary: Shen et al. reported on the genetic analyses of 7 patients with CCDS. The children were between the ages of 2 and 8 years old and all had some form of intellectual disability or motor developmental delay. All patients had low creatine levels and genetic variations on either the SLC6A8 gene or GAMT gene. The authors noted that the definite type of CCDS for these 7 patients remains to be determined. With respect to the genetic testing, the authors identified 12 genetic variations in the 7 patients, with 6 of the variations being novel. The authors concluded that their data expands the spectrum of possible genetic variations underlying CCDS, which may help with future genetic counseling for families.

Link to free article: Identification of novel variations in SLC6A8 and GAMT genes causing cerebral creatine deficiency syndrome

Link to PubMed: PubMed

Scientific Abstract: Introduction: Cerebral creatine deficiency syndromes (CCDS) are a group of potentially treatable neurometabolic disorders. The clinical, genetic profile and follow up outcome of Indian CCDS patients is presented. Materials and methods: This was a retrospective cohort of CCDS patients seen over six-years. Diagnosis was based either on low creatine peak on proton magnetic resonance spectroscopy (MRS) and/or genetic evaluation. Results: Thirteen patients were eligible [8 creatine transporter deficiency (CTD), 4 guanidinoacetate methyltransferase (GAMT) deficiency and 1 could not be classified]. The mean (±SD) age at diagnosis was 7.2(±5.0) years. Clinical manifestations included intellectual disability (ID) with significant expressive speech delay in all. Most had significant behavior issues (8/13) and/or autism (8/13). All had history of convulsive seizures (11/13 had epilepsy; 2 patients only had febrile seizures) and 2/13 had movement disorder. Constipation was the commonest non-neurological manifestation (5/13 patients). Cranial MRI was normal in all CTD patients but showed globus pallidus hyperintensity in all four with GAMT deficiency. MRS performed in 11/13 patients, revealed abnormally low creatine peak. A causative genetic variant (novel mutation in nine) was identified in 12 patients. Three GAMT deficiency and one CTD patient reported neurodevelopmental improvement and good seizure control after creatine supplementation. Conclusion: Intellectual disability, disproportionate speech delay, autism, and epilepsy, were common in our CCDS patients. A normal structural neuroimaging with easily controlled febrile and/or afebrile seizures differentiated CTD from GAMT deficiency patients who had abnormal neuroimaging and often difficult to control epilepsy and movement disorder.

Link to abstract on PubMed: Cerebral creatine deficiency disorders – A clinical, genetic and follow up study from India

ACD Summary: Magnetic resonance spectroscopy (MRS) of the brain is a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues. It was actually the technique used to discover creatine deficiency in the brain. Here, for the first time with respect to CTD), Li et al. used a type of MRS called phosphorus MRS, which provides a better glimpse into energy metabolism in the brain. Even though levels of creatine and phosphocreatine (which are reduced in patients with CTD) are critical for energy metabolism in the brain, these authors did not find evidence to suggest energy metabolism differed in patients with CTD. Because the reduced phosphocreatine may reflect changes in how mitochondria are functioning (i.e., mitochondria are responsible for energy production), these authors suggest that development and application of techniques to enhance the brain’s mitochondrial function may benefit patients with CTD.

Link to free article on PubMed: Oxidative Phosphorylation in Creatine Transporter Deficiency

ACD Summary: This report describes treatment of a 5-year-old boy (diagnosed with CTD at 3.25 years old) with high-dose creatine supplementation, beginning at 4.5 years of age. The dose of creatine supplementation increased over the course of 6 months, up to 1200 mg per kg per day. While there was no significant improvement in cognition function or brain creatine levels, there was improvement in muscle mass, strength, and coordination.

Link to free article: Treatment efficacy of high-dose creatine supplementation in a child with creatine transporter (SLC6A8) deficiency

Link to PubMed: PubMed

ACD Summary: Levin et al. studied the cardiac profile of 18 boys with CTD. To do so, they analyzed the QTc interval, which reflects heart rhythm. Long QTc intervals (and long QT syndrome) may lead to heart conditions, like arrhythmia. One common designation for what counts as a long QTc interval is 450 milliseconds. Here, of the 18 patients with CTD, 7 of them had QTc intervals greater than 470 milliseconds (i.e., prolonged QTc intervals). Similar results were observed in an animal model of CTD. These authors recommend that newly diagnosed CTD patients have an electrocardiogram and an echocardiogram to measure heart rhythm (and to avoid medications that may lead to prolonged QTc intervals).

Link to free article: X-linked creatine transporter deficiency results in prolonged QTc and increased sudden death risk in humans and disease model

Link to PubMed: PubMed

Scientific Abstract: Creatine is pivotal in energy metabolism of the brain. In primary creatine deficiency syndromes, creatine is missing from the brain. Two of them (AGAT and GAMT deficiency) are due to impaired creatine synthesis, and can be treated by creatine supplementation. By contrast, creatine transporter deficiency cannot be treated by such supplementation, since creatine crossing of biological membranes (plasma membrane and blood-brain barrier) is dependent on its transporter. This problem might be overcome by modifying the creatine molecule to allow it to cross biological membranes independently of its transporter. Thus, we designed and synthesized di-acetyl creatine ethyl ester (DAC), a compound that should cross biological membranes independently of the transporter due to its very high lipophilicity. We investigated its ability to increase intracellular creatine levels even after block of creatine transporter, and to counter cell damage induced by transporter block. In our experiments after block of the creatine transporter, DAC was able both to prevent electrophysiological failure and to increase intracellular creatine. Interestingly, it did so in micromolar concentrations, at variance with all the other creatine derivatives that we know of.

Link to abstract on PubMed: Di-acetyl creatine ethyl ester, a new creatine derivative for the possible treatment of creatine transporter deficiency

ACD Summary: Bruun et al. surveyed the physicians of 17 patients with CTD (from 16 unrelated families) on the severity of each patient’s (1) global developmental delay/intellectual disability, (2) seizures, and (3) behavioral disorders. All patients showed global developmental delays/intellectual disabilities; 8 had seizures; 9 had behavioral disorders (with autism spectrum disorder and ADHD being the most common). The authors derived an overall severity score phenotype (which refers to a set of observable traits) by collapsing the 3 individual severity scores: 7 patients had a “mild” phenotype; 6 patients had a “moderate” phenotype; 4 patients had a “severe” phenotype. There was no correlation between overall severity score and age of diagnosis or between overall severity score and urine creatine:creatinine levels. The authors suggested that while combined creatine, arginine, and glycine therapy might have stopped the progression of the disease in males and might have improved the phenotype in females, the overall severity score did not considerably change during treatment.

Link to abstract on PubMed: Treatment outcome of creatine transporter deficiency: international retrospective cohort study

Scientific Abstract: Creatine transporter is currently the focus of renewed interest with emerging roles in brain neurotransmission and physiology, and the bioenergetics of cancer metastases. We here report on amendments of a standard creatine uptake assay which might help clinical chemistry laboratories to extend their current range of measurements of creatine and metabolites in body fluids to functional enzyme explorations. In this respect, short incubation times and the use of a stable-isotope-labeled substrate (D3-creatine) preceded by a creatine wash-out step from cultured fibroblast cells by removal of fetal bovine serum (rich in creatine) from the incubation medium are recommended. Together, these measures decreased, by a first order of magnitude, creatine concentrations in the incubation medium at the start of creatine-uptake studies and allowed to functionally discriminate between 4 hemizygous male and 4 heterozygous female patients with X-linked SLC6A8 deficiency, and between this cohort of eight patients and controls. The functional assay corroborated genetic diagnosis of SLC6A8 deficiency. Gene anomalies in our small cohort included splicing site (c.912G > A [p.Ile260_Gln304del], c.778-2A > G and c.1495 + 2 T > G), substitution (c.407C > T) [p.Ala136Val] and deletion (c.635_636delAG [p.Glu212Valfs*84] and c.1324delC [p.Gln442Lysfs*21]) variants with reduced creatine transporter function validating their pathogenicity, including that of a previously unreported c.1324delC variant. The present assay adaptations provide an easy, reliable and discriminative manner for exploring creatine transporter activity and disease variations. It might apply to drug testing or other evaluations in the genetic and metabolic horizons covered by the emerging functions of creatine and its transporter, in a way, however, requiring and completed by additional studies on female patients and blood-brain barrier permeability properties of selected compounds. As a whole, the proposed assay of creatine transporter positively adds to currently existing measurements of this transporter activity, and determining on a large scale the extent of its exact suitability to detect female patients should condition in the future its transfer in clinical practice.

Link to abstract on PubMed: Functional assessment of creatine transporter in control and X-linked SLC6A8-deficient fibroblasts

ACD Summary: Sharer et al. reported on recommended laboratory methods to diagnose CCDSs. While the authors noted that magnetic resonance spectroscopy (MRS; a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues) can be used, that approach is expensive, requires children to be sedated, and does not specify which CCDS the patient may have. Thus, the authors recommended measuring creatine, guanidinoacetate, and creatinine levels in urine, plasma, or dried blood spots for initial diagnosis. For AGAT or GAMT deficiency, plasma and/or urine can be used; measurements of creatine and guanidinoacetate levels in plasma are specifically recommended. For CTD, urine is the best option. For some female patients with CTD, genetic analyses are also recommended. In general, the authors recommend that the samples be collected when the patients have fasted. The authors also provided a general reference table for relative levels of guanidinoacetate, creatine, and creatine:creatinine ratios in plasma, urine, and cerebrospinal fluid in patients with AGAT deficiency, GAMT deficiency, and CTD. (Cerebrospinal fluid is a fluid that flows through the brain and spinal cord.) The authors did note that creatinine (by itself) has limited value as a diagnostic marker for CCDSs. Additionally, the authors  provided background information on (1) the sources and function of creatine, (2) biochemical/molecular characteristics and clinical descriptions of AGAT, GAMT, and CTD, (3) prevalence and inheritance of CCDSs, and (4) interpretation of test results.

Link to free article: Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics

Link to PubMed: PubMed

Scientific Abstract: Background: Creatine transporter deficiency (CTD) is an X-linked inborn error of creatine metabolism characterized by reduced intra-cerebral creatine, developmental delay/intellectual disability, (ID), behavioral disturbance, seizures, and hypotonia in individuals harboring mutations in the SLC6A8 gene. Treatment for CTD includes supplementation with creatine, either alone or in combination with creatine precursors (arginine or glycine). Unlike other disorders of creatine metabolism, the efficacy of its treatment remains controversial. Methods: We present our systematic literature review (2001-2013) comprising 7 publications (case series/reports), collectively describing 25 patients who met the inclusion criteria, and 3 additional cases treated at our institution. Definitions were established and extracted data analyzed for cognitive ability, psychiatric and behavioral disturbances, epilepsy, and cerebral proton magnetic resonance spectroscopy measurements at pre- and post-treatment. Results: Treatment regimens varied among the 28 cases: 2 patients received creatine-monohydrate supplementation; 7 patients received L-arginine; 2 patients received creatine-monohydrate and L-arginine; and 17 patients received a combination of creatine-monohydrate, L-arginine and glycine. Median treatment duration was 34.6 months (range 3 months-5 years). Level of evidence was IV. A total of 10 patients (36%) demonstrated response to treatment, manifested by either an increase in cerebral creatine, or improved clinical parameters. Seven of the 28 patients had quantified pre- and post-treatment creatine, and it was significantly increased post-treatment. All of the patients with increased cerebral creatine also experienced clinical improvement. In addition, the majority of patients with clinical improvement had detectable cerebral creatine prior to treatment. 90% of the patients who improved were initiated on treatment before nine years of age. Conclusions: Acknowledging the limitations of this systematic review, we conclude that a proportion of CTD patients show amenability to treatment-particularly milder cases with residual brain creatine, and therefore probable residual protein function. We propose systematic screening for CTD in patients with ID, to allow early initiation of treatment, which currently comprises oral creatine, arginine and/or glycine supplementation. Standardized monitoring for safety and evaluation of treatment effects are required in all patients. This study provides effectiveness on currently available treatment, which can be used to discern effectiveness of future interventions (e.g. cyclocreatine).

Link to abstract on PubMed: Treatment of X-linked creatine transporter (SLC6A8) deficiency: systematic review of the literature and three new cases

Scientific Abstract: Background: Creatine transporter deficiency is a monogenic cause of X-linked intellectual disability. Since its first description in 2001 several case reports have been published but an overview of phenotype, genotype and phenotype–genotype correlation has been lacking. Methods: We performed a retrospective study of clinical, biochemical and molecular genetic data of 101 males with X-linked creatine transporter deficiency from 85 families with a pathogenic mutation in the creatine transporter gene (SLC6A8). Results and conclusions: Most patients developed moderate to severe intellectual disability; mild intellectual disability was rare in adult patients. Speech language development was especially delayed but almost a third of the patients were able to speak in sentences. Besides behavioural problems and seizures, mild to moderate motor dysfunction, including extrapyramidal movement abnormalities, and gastrointestinal problems were frequent clinical features. Urinary creatine to creatinine ratio proved to be a reliable screening method besides MR spectroscopy, molecular genetic testing and creatine uptake studies, allowing definition of diagnostic guidelines. A third of patients had a de novo mutation in the SLC6A8 gene. Mothers with an affected son with a de novo mutation should be counselled about a recurrence risk in further pregnancies due to the possibility of low level somatic or germline mosaicism. Missense mutations with residual activity might be associated with a milder phenotype and large deletions extending beyond the 3′ end of the SLC6A8 gene with a more severe phenotype. Evaluation of the biochemical phenotype revealed unexpected high creatine levels in cerebrospinal fluid suggesting that the brain is able to synthesise creatine and that the cerebral creatine deficiency is caused by a defect in the reuptake of creatine within the neurones.

Link to abstract on PubMed: Phenotype and genotype in 101 males with X-linked creatine transporter deficiency

ACD Summary: Fons et al. studied whether dietary supplementation with creatine monohydrate (CM) or creatine ethyl ester (CEE) (both of which can be purchased commerically in powder form) had clinical benefits. First, the researchers showed that CEE crossed the plasma membrane of fibroblasts (which are types of cells that help connect the body’s tissue together). Thus, they explored whether CEE supplementation would have benefits in patients with CTD. However, after 1 year of treatment with CEE supplementation, while there were no adverse effects, there were also no improvements in communication, daily living skills, socialization, or motor skills in these patients; also, there was not an increase in creatine in the brain. Because there were positive results with the fibroblast cells, there is reason for future research exploring mechanisms of cellular transport of CEE, but these authors do not recommend CEE treatment for patients with CTD.

Link to abstract on PubMed: Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency

Scientific Abstract: Mutations in the creatine transporter gene, SLC6A8 (MIM 30036), located in Xq28, have been found in families with X-linked mental retardation (XLMR) as well as in males with idiopathic mental retardation (MR). In order to estimate the frequency of such mutations in the MR population, a screening of 478 males with MR of unknown cause was undertaken. All 13 exons of SLC6A8 were sequenced using genomic DNA. Six novel potentially pathogenic mutations were identified that were not encountered in at least 588 male control chromosomes: two deletions (p.Asn336del, p.Ile347del) and a splice site alteration (c.1016+2C>T) are considered pathogenic based on the nature of the variant. A mutation (p.Arg391Trp) should be considered pathogenic owing to its localization in a highly conserved region. Two other missense variants (p.Lys4Arg, p.Gly26Arg) are not conserved but were not observed in over 300 male control chromosomes. Their pathogenicity is uncertain. A missense variant (p.Val182Met), was classified as a polymorphism based on a normal creatine/creatinine (Cr:Crn) ratio and cerebral creatine signal in proton magnetic resonance spectroscopy (H-MRS) in the patient. Furthermore, we found 14 novel intronic and neutral variants that were not encountered in at least 280 male control chromosomes and should be considered as unclassified variants. Our findings of a minimum of four pathogenic mutations and two potentially pathogenic mutations indicate that about 1% of males with MR of unknown etiology might have a SLC6A8 mutation. Thus, DNA sequence analysis and/or a Cr:Crn urine screen is warranted in any male with MR of unknown cause.

Link to abstract on PubMed: X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology

ACD Summary: In this brief yet seminal study, Salomons et al. reported the first case of CTD. The patient had a mild intellectual disability and a severe speech delay. Magnetic resonance spectroscopy (MRS) revealed that there was no creatine in the brain. (MRS is a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues.) While the absence of a creatine signal is also seen in patients with a GAMT deficiency, this patient’s urine and plasma guanidinoacetate levels were normal, and treatment with creatine monohydrate did not increase creatine in the brain. So, GAMT deficiency was ruled out. The authors found that there was a history of a learning disability in the mother and maternal grandmother and a severe intellectual disability in the mother’s brother. The mother’s sister and mother also had a reduced creatine MRS signal. These data led the authors to speculate that the patient had an X-linked chromosome disorder. (All individuals have at least 1 X chromosome, but those with only 1 X chromosome are more likely to be affected by genetic mutations on the X chromosome.) The authors hypothesized that the patient had a mutation on the creatine-transporter gene SLC6A8, which was confirmed through laboratory analyses of cells from the patient.

Link to free article on PubMed: X-Linked Creatine-Transporter Gene (SLC6A8) Defect: A New Creatine-Deficiency Syndrome

Scientific Abstract: We have generated a stable HEK293 cell line expressing high levels of a creatine transporter (CREAT). This cell line (HEK293-CREAT) was used to study the properties of CREAT in terms of the accumulation and release of creatine. HEK293-CREAT cells accumulated high steady state levels of creatine under saturating creatine levels (approx. 25-fold higher intracellular creatine levels than seen in control cells). The accumulation of high levels of creatine affected [3H]creatine uptake by decreasing the Vmax for transport. High intracellular creatine levels were maintained in the absence of extracellular creatine. External creatine stimulated the release of stored creatine by an exchange mechanism dependent on extracellular Na+. These studies have shown that cellular creatine levels can be affected by the amount of creatine transporter in the membrane and exchange through the creatine transporter. These findings highlight the importance of the creatine transporter in the maintenance of intracellular creatine levels.

Link to abstract on PubMed: Creatine accumulation and exchange by HEK293 cells stably expressing high levels of a creatine transporter

Scientific Abstract: Background: Targeting the enzyme L-Arginine:glycine amidinotransferase (AGAT) to reduce the formation of guanidinoacetate (GAA) in patients with guanidinoacetate methyltransferase (GAMT) deficiency, we attempted to identify drugs for repurposing that reduce the expression of AGAT via transcriptional inhibition.

Research Design and Methods: The authors applied a HeLa cell line stably expressing AGAT promoter and firefly luciferase reporter for high-content screening and secondary screening. For further assessment, the authors integrated Nanoluc luciferase as a reporter into the endogenous AGAT gene in HAP1 cell lines and used the human immortalized cell line RH30 as model of GAMT deficiency.

Results: Screening 6,000 drugs and drug-like compounds, the authors identified 43 and 34 high-score candidates as inhibitors and inducers of AGAT promoter-reporter expression, respectively. After further deselection considering dose response, drug toxicity, topical formulations, price, and accessibility, the
authors assessed seven candidates and found none of them demonstrating efficacy in HAP1 and RH30 cells and warranting further assessment.

Conclusion: The selection of the test models is crucial for screening of gene repressor drugs. Almost all drugs with an impact on gene expression had off-target effects. It is unlikely to find drugs that are selective inhibitors of AGAT expression, rendering pharmacological AGAT gene repression a risky approach for the treatment of GAMT deficiency.

Link to free article: Targeting AGAT gene expression – a drug screening approach for the treatment of GAMT deficiency

ACD Summary: Sun et al. screened for the presence of a CCDS in 3,586 patients who exhibited a developmental delay. Screening involved measuring creatine and guanidinoacetate (GAA) levels in blood, creatine:creatinine levels in urine, and creatine signals in the brain. In total, 14 patients had a confirmed CCDS (6 with GAMT deficiency, 8 with CTD). There were also brain structural differences in some of the patients. In patients with GAMT deficiency, treatment involved a low-protein diet and supplementation with creatine and ornithine. After 2 to 3 weeks of treatment, creatine and GAA levels in blood returned to a normal range; after 6 to 9 months, their brain’s creatine signals increased dramatically. In 3 patients with GAMT deficiency, epilepsy was resolved after 3 to 6 months of treatment. Overall, treatment was associated with a general improvement in the children with GAMT deficiency. For patients with CTD, there was minimal (if any) improvement given supplementation treatment with creatine, glycine, and/or arginine. In conclusion, the authors recommended that patients with a developmental delay, feeding or growth difficulties, and epilepsy should be screened for CCDS.

Link to free article on PubMed: Fourteen cases of cerebral creatine deficiency syndrome in children: a cohort study in China

Scientific Abstract: Introduction: Guanidinoacetate methyltransferase (GAMT) deficiency, also known as cerebral creatine deficiency syndrome type 2 (CCDS2), is an uncommon disease caused by an innate genetic defect in the metabolic pathway of creatine inherited in an autosomal recessive manner. It is a rare cause of neurological regression and epilepsy. In this report, we present the first GAMT deficiency case in Syria related to a novel variant. Case Presentation: A 2.5-year-old boy presented to the paediatric neurology clinic with evidence of neurodevelopmental delays and intellectual disabilities. Recurrent eye blinking, generalized non-motor (absence) seizures, hyperactivity, and poor eye contact were revealed in the neurological examination. Some athetoid and dystonic movements were noticed. His electroencephalography (EEG) was very disturbed because of generalized spike-wave and slow-wave discharges. Based on these findings antiepileptic drugs were administered. His seizures slightly improved, but then relapsed with myoclonic and drop attacks. After 6 years of unbeneficial treatment, a genetic test was required. Whole-exome sequencing was conducted and identified a novel homozygous GAMT variant (NM_138924.2:c.391+5G>C). Treatment with oral creatine supplementation, ornithine, and sodium benzoate was administered. After 1.7 years of follow-up, the child was almost seizure-free with a remarkable reduction of epileptic activity on EEG. He demonstrated good—but not complete—behavioural and motor improvement due to delayed diagnosis and treatment. Conclusion: GAMT deficiency should be considered in differential diagnoses in children with neurodevelopmental regression along with drug-refractory epilepsy. A special concern is needed in Syria for such genetic disorders; regarding the high prevalence of consanguinity. Whole-exome sequencing and genetic analysis can be used to diagnose this disorder. We reported a novel GAMT variant to extend its mutation spectrum and provide an additional molecular marker for the definitive diagnosis of GAMT deficiency patients and prenatal diagnosis in the affected families.

Link to free article on PubMed: Novel guanidinoacetate methyltransferase (GAMT) mutation associated with cerebral creatine deficiency syndrome in a Syrian child: a case report

ACD Summary: Mustafa et al. analyzed levels of guanidinoacetic acid (GAA), creatine, and creatinine in urine in neurotypical children ages 0- to 15-years-old in Egypt. Specifically, the authors looked at the ratio of GAA to creatinine (GAA:creatinine) and the ratio of creatine to creatinine (creatine:creatinine). Typically, GAA:creatinine levels in urine are low in patients with AGAT deficiency, elevated in patients with GAMT deficiency, and normal in patients with CTD. In contrast, creatine:creatinine levels in urine are normal in patients with AGAT or GAMT deficiency and may be elevated in patients with CTD. These ratios are used by physicians to help with diagnosing CCDS. Accordingly, Mustafa et al. wanted to determine how these ratio levels change with age, so they could begin to establish an age-specific reference level for these diagnostic criteria. The authors collected data on 160 children but removed 10 children from analysis because of positive screening for a CCDS. For the remaining 150 neurotypical children, there was a steady decline in GAA:creatinine and creatine:creatinine levels with age, with there being a large difference in these average levels when comparing children less than 4 years old to children between 4 and 15 years old. Accordingly, the reference criteria for diagnosing CCDS may change with age at time of diagnosis, which may be contributing to the underdiagnosis of CCDS.

Link to free article: Age Adjusted Reference Interval for Creatine Deficiency Syndrome Biomarkers by Gas chromatography-Mass Spectrometry

Scientific Abstract: Creatine deficiency syndromes (CDS) are inherited metabolic disorders caused by mutations in GATM, GAMT and SLC6A8 and mainly affect central nervous system (CNS). AGAT- and GAMT-deficient patients lack the functional brain endogenous creatine (Cr) synthesis pathway but express the Cr transporter SLC6A8 at blood-brain barrier (BBB), and can thus be treated by oral supplementation of high doses of Cr. For Cr transporter deficiency (SLC6A8 deficiency or CTD), current treatment strategies benefit one-third of patients. However, as their phenotype is not completely reversed, and for the other two-thirds of CTD patients, the development of novel more effective therapies is needed. This article aims to review the current knowledge on Cr metabolism and CDS clinical aspects, highlighting their current treatment possibilities and the most recent research perspectives on CDS potential therapeutics designed, in particular, to bring new options for the treatment of CTD.

Link to free article: Current and potential new treatment strategies for creatine deficiency syndromes

Link to PubMed: PubMed

Scientific Abstract: Introduction: Cerebral creatine deficiency syndromes (CCDS) are a group of potentially treatable neurometabolic disorders. The clinical, genetic profile and follow up outcome of Indian CCDS patients is presented. Materials and methods: This was a retrospective cohort of CCDS patients seen over six-years. Diagnosis was based either on low creatine peak on proton magnetic resonance spectroscopy (MRS) and/or genetic evaluation. Results: Thirteen patients were eligible [8 creatine transporter deficiency (CTD), 4 guanidinoacetate methyltransferase (GAMT) deficiency and 1 could not be classified]. The mean (±SD) age at diagnosis was 7.2(±5.0) years. Clinical manifestations included intellectual disability (ID) with significant expressive speech delay in all. Most had significant behavior issues (8/13) and/or autism (8/13). All had history of convulsive seizures (11/13 had epilepsy; 2 patients only had febrile seizures) and 2/13 had movement disorder. Constipation was the commonest non-neurological manifestation (5/13 patients). Cranial MRI was normal in all CTD patients but showed globus pallidus hyperintensity in all four with GAMT deficiency. MRS performed in 11/13 patients, revealed abnormally low creatine peak. A causative genetic variant (novel mutation in nine) was identified in 12 patients. Three GAMT deficiency and one CTD patient reported neurodevelopmental improvement and good seizure control after creatine supplementation. Conclusion: Intellectual disability, disproportionate speech delay, autism, and epilepsy, were common in our CCDS patients. A normal structural neuroimaging with easily controlled febrile and/or afebrile seizures differentiated CTD from GAMT deficiency patients who had abnormal neuroimaging and often difficult to control epilepsy and movement disorder.

Link to abstract on PubMed: Cerebral creatine deficiency disorders – A clinical, genetic and follow up study from India

ACD Summary: Shen et al. reported on the genetic analyses of 7 patients with CCDS. The children were between the ages of 2 and 8 years old and all had some form of intellectual disability or motor developmental delay. All patients had low creatine levels and genetic variations on either the SLC6A8 gene or GAMT gene. The authors noted that the definite type of CCDS for these 7 patients remains to be determined. With respect to the genetic testing, the authors identified 12 genetic variations in the 7 patients, with 6 of the variations being novel. The authors concluded that their data expands the spectrum of possible genetic variations underlying CCDS, which may help with future genetic counseling for families.

Link to free article: Identification of novel variations in SLC6A8 and GAMT genes causing cerebral creatine deficiency syndrome

Link to PubMed: PubMed

ACD Summary: Modi et al. described the presence of developmental delays, cognitive impairments, excessive drooling, bone deformities, behavioral abnormalities, and little to no language comprehension in 2 untreated, adult opposite-sex siblings with GAMT deficiency in Pakistan (ages 23-25). They also shared a genetic variant (c.134G > A; p.Trp45*) that had not been seen previously in adult GAMT cases. After starting creatine supplementation in the female adult sibling, no further deterioration was observed. These 2 patients had a similar disease progression as 21 other patients with GAMT deficiency in 8 other studies. These authors recommend (1) further study of GAMT deficiency to better understand its progression and (2) widespread implementation of newborn screening programs, especially in Pakistan.

Link to free article: Adult GAMT deficiency: A literature review and report of two siblings

Link to PubMed: PubMed

ACD Summary: Narayan et al. described the cases of 3 patients with GAMT (2 of them being from the same family). When Child A was 1-year-old, a series of disorders were considered for diagnosis (such as Angelman syndrome and Mowat-Wilson syndrome), but he lacked the syndromes characteristic of these disorders. When he was 2 years old, genetic analyses supported a GAMT diagnosis. Treatment with oral creatine monohydrate (starting at age 2) led to motor improvements, but he continued to show speech and behavioral problems. Childs B and C (ages 8 and 10 years old) underwent genetic testing, which subsequently supported a GAMT diagnosis. After 6 months of treatment with oral creatine monohydrate, both children showed minor improvements in gait, sleep, and hyperactivity. These results led the authors to advocate for CCDS screening in every child with developmental delays (especially those with a happy disposition and low serum creatinine).

Link to free article on PubMed: Case Series of Creatine Deficiency Syndrome due to Guanidinoacetate Methyltransferase Deficiency

ACD Summary: Yoganathan et al. reported on a 29-month-old patient with neurodevelopmental delays. Data were collected using magnetic resonance spectroscropy (MRS), which is a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues. The MRS revealed cerebral creatine deficiency, and a urine test showed increased excretion of guanidinoacetate, which collectively supported a diagnosis of GAMT. After 9 months of treatments of creatine monohydrate (coupled with a low protein diet), there were improvements in socio-cognitive skills, and cerebral creatine (per MRS) was present. In conclusion, these authors argued for CCDS screening when a child has an unexplained neurodevelopmental disorder coupled with the presence of symptoms related to autism, seizures, movement disorders, or muscle weakness.

Link to free article on PubMed: Guanidinoacetate Methyltransferase (GAMT) Deficiency, A Cerebral Creatine Deficiency Syndrome: A Rare Treatable Metabolic Disorder

Scientific Abstract: Arginine:glycine amidinotransferase- and guanidinoacetate methyltransferase deficiency are severe neurodevelopmental disorders. It is not known whether mouse models of disease express a neuroanatomical phenotype. High-resolution magnetic resonance imaging (MRI) with advanced image analysis was performed in perfused, fixed mouse brains encapsulated with the skull from male, 10-12 week old Agat -exc and B6J.Cg-Gamt tm1Isb mice (n = 48; n = 8 per genotype, strain). T2-weighted MRI scans were nonlinearly aligned to a 3D atlas of the mouse brain with 62 structures identified. Local differences in brain shape related to genotype were assessed by analysis of deformation fields. Creatine (Cr) and guanidinoacetate (GAA) were measured with high-performance liquid chromatography (HPLC) in brain homogenates (n = 24; n = 4 per genotype, strain) after whole-body perfusion. Cr was decreased in the brain of Agat- and Gamt mutant mice. GAA was decreased in Agat-/- and increased in Gamt-/- . Body weight and brain volume were lower in Agat-/- than in Gamt-/- . The analysis of entire brain structures revealed corpus callosum, internal capsule, fimbria and hypothalamus being different between the genotypes in both strains. Eighteen and fourteen significant peaks (local areas of difference in relative size) were found in Agat- and Gamt mutants, respectively. Comparing Agat-/- with Gamt-/- , we found changes in three brain regions, lateral septum, amygdala, and medulla. Intra-strain differences in four brain structures can be associated with Cr deficiency, while the inter-strain differences in three brain structures of the mutant mice may relate to GAA. Correlating these neuroanatomical findings with gene expression data implies the role of Cr metabolism in the developing brain and the importance of early intervention in patients with Cr deficiency syndromes.

Link to abstract on PubMed: Magnetic resonance imaging reveals specific anatomical changes in the brain of Agat- and Gamt-mice attributed to creatine depletion and guanidinoacetate alteration

Scientific Abstract: Creatine is synthesized by S-adenosylmethionine:guanidinoacetate N-methyltransferase (GAMT), and the creatine/phosphocreatine shuttle system mediated by creatine kinase (CK) is essential for storage and regeneration of high-energy phosphates in cells. Although the importance of this system in brain development is evidenced by the hereditary nature of creatine deficiency syndrome, the spatiotemporal cellular expression patterns of GAMT in developing brain remain unknown. Here we show that two waves of high GAMT expression occur in developing mouse brain. The first involves high expression in mitotic cells in the ventricular zone of the brain wall and the external granular layer of the cerebellum at the embryonic and neonatal stages. The second was initiated by striking up-regulation of GAMT in oligodendrocytes during the second and third postnatal weeks (i.e., the active myelination stage), which continued to adulthood. Distinct temporal patterns were also evident in other cell types. GAMT was highly expressed in perivascular pericytes and smooth muscle cells after birth, but not in adults. In neurons, GAMT levels were low to moderate in neuroblasts residing in the ventricular zone, increased during the second postnatal week when active dendritogenesis and synaptogenesis occur, and decreased to very low levels thereafter. Moderate levels were observed in astrocytes throughout development. The highly regulated, cell type-dependent expression of GAMT suggests that local creatine biosynthesis plays critical roles in certain phases of neural development. In accordance with this idea, we observed increased CK expression in differentiating neurons; this would increase creatine/phosphocreatine shuttle system activity, which might reflect increased energy demand.

Link to abstract on PubMed: Cell-Type-Specific Spatiotemporal Expression of Creatine Biosynthetic Enzyme S-adenosylmethionine:guanidinoacetate N-methyltransferase in Developing Mouse Brain

Scientific Abstract: Purpose: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder caused by pathogenic variants in GAMT. Brain creatine depletion and guanidinoacetate accumulation cause developmental delay, seizures and movement disorder. Treatment consists of creatine, ornithine and arginine-restricted diet. We initiated an international treatment registry using Research Electronic Data Capture (REDCap) software to evaluate treatment outcome. Methods: Physicians completed an online REDCap questionnaire. Clinical severity score applied pre-treatment and on treatment. Results: There were 22 patients. All had developmental delay, 18 had seizures and 8 had movement disorder. Based on the clinical severity score, 5 patients had a severe, 14 patients had a moderate and 3 patients had a mild phenotype. All patients had pathogenic variants in GAMT. The phenotype ranged from mild to moderate in patients with the most common c.327G > A variant. The phenotype ranged from mild to severe in patients with truncating variants. All patients were on creatine, 18 patients were on ornithine and 15 patients were on arginine- or protein-restricted diet. Clinical severity score improved in 13 patients on treatment. Developmental delay improved in five patients. One patient achieved normal development. Eleven patients became seizure free. Movement disorder resolved in four patients. Conclusion: In our small patient cohort, there seems to be no phenotype–genotype correlation. Creatine and ornithine and/or arginine- or protein-restricted diet were the most useful treatment to improve phenotype.

Link to abstract on PubMed: Treatment outcome of twenty-two patients with guanidinoacetate methyltransferase deficiency: An international retrospective cohort study

ACD Summary: Sharer et al. reported on recommended laboratory methods to diagnose CCDSs. While the authors noted that magnetic resonance spectroscopy (MRS; a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues) can be used, that approach is expensive, requires children to be sedated, and does not specify which CCDS the patient may have. Thus, the authors recommended measuring creatine, guanidinoacetate, and creatinine levels in urine, plasma, or dried blood spots for initial diagnosis. For AGAT or GAMT deficiency, plasma and/or urine can be used; measurements of creatine and guanidinoacetate levels in plasma are specifically recommended. For CTD, urine is the best option. For some female patients with CTD, genetic analyses are also recommended. In general, the authors recommend that the samples be collected when the patients have fasted. The authors also provided a general reference table for relative levels of guanidinoacetate, creatine, and creatine:creatinine ratios in plasma, urine, and cerebrospinal fluid in patients with AGAT deficiency, GAMT deficiency, and CTD. (Cerebrospinal fluid is a fluid that flows through the brain and spinal cord.) The authors did note that creatinine (by itself) has limited value as a diagnostic marker for CCDSs. Additionally, the authors  provided background information on (1) the sources and function of creatine, (2) biochemical/molecular characteristics and clinical descriptions of AGAT, GAMT, and CTD, (3) prevalence and inheritance of CCDSs, and (4) interpretation of test results.

Link to free article: Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics

Link to PubMed: PubMed

ACD Summary: Stockler-Ipsiroglu et al. described treatments and outcomes in 48 patients with GAMT, 44 of whom were diagnosed after 9 months of age and showed developmental delays and/or intellectual disability. The other 4 patients did not exhibit such symptoms. 46 of the 48 patients received creatine-monohydrate as the key treatment, with other additional dietary and/or pharmaceutical treatments varying across patients, so as to ultimately reduce levels of guanidinoacetate (GAA). For the majority of patients, treatment led to clinical improvements. These authors note that determining urinary GAA and/or plasma GAA is the preferred method for screening, and that diagnosis can be confirmed by a genetic analysis; noninvasive magnetic resonance spectroscopy is not necessary if diagnosis is confirmed by GAA and genetic analysis. The authors also recommend monitoring GAA levels in plasma.

Link to free article: Guanidinoacetate methyltransferase (GAMT) deficiency: Outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring

Link to PubMed: PubMed

ACD Summary: Akiyama et al. described the first known Japanese case of GAMT deficiency, a 38-year-old female patient with 2 novel genetic markers of GAMT deficiency. The patient developed epilepsy when 18 months old, showed minimal (if any) language comprehension, had developmental delays, and continued to exhibit trichotillomania (hair-pulling) into adulthood. When the patient turned 30, mobility started to decline. The patient started a regimen of creatine and ornithine supplementation at 38 years old, but the outcomes of the treatment were not reported in this report. These results led the authors to further recommend neonatal screening for GAMT deficiency.

Link to free article on PubMed: A Japanese Adult Case of Guanidinoacetate Methyltransferase Deficiency

Scientific Abstract: Guanidinoacetate methyltransferase (GAMT) deficiency is a good candidate disorder for newborn screening because early treatment appears to improve outcomes. We report elevation of guanidinoacetate in archived newborn dried blood spots for 3 cases (2 families) of GAMT deficiency compared with an unaffected carrier and controls. We also report a new case of a patient treated from birth with normal developmental outcome at the age of 42 months.

Link to abstract on PubMed: Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency

Scientific Abstract: Background: Guanidinoacetate methyltransferase (GAMT) deficiency causes cerebral creatine deficiency. Patients can have autistic behavior, seizures, intellectual disability, and severe speech delay. The goal of therapy is to increase creatine while reducing potentially neurotoxic guanidinoacetate concentrations. Here we evaluate how different therapies affect plasma guanidinoacetate levels in patients with GAMT deficiency. Methods: Retrospective analysis of data from five new patients with GAMT deficiency (four with delays and seizures, one diagnosed at birth). Results: The four symptomatic patients had decreased brain creatine by magnetic resonance spectroscopy and three also had abnormal globi pallidi by MRI. GAMT sequencing identified four previously reported mutations and one novel missense mutation (c.233T>A/p.V78E). Treatment with creatine (250–1000 mg/kg/day), ornithine (100–800 mg/kg/day), and sodium benzoate (50–135 mg/kg/day) supplements along with dietary protein restriction (0.8–1.5 g/kg/day) improved seizures and development with all patients becoming verbal. The patient treated at birth remains developmentally normal. Reduction in glycine and increase in ornithine levels significantly decreased plasma guanidinoacetate, with glycine levels being the best predictor of guanidinoacetate levels. In contrast, arginine levels were not significantly correlated with plasma guanidinoacetate. Conclusions: Our results show that supplements of creatine, sodium benzoate (to reduce glycine) and ornithine reduce guanidinoacetate levels in patients with GAMT deficiency (dietary therapy was not evaluated in our study). Normal development with early therapy renders GAMT deficiency an ideal candidate for inclusion in newborn screening panels.

Link to abstract on PubMed: Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency

ACD Summary: Caldeira Araújo et al. explored the prevalence of GAMT deficiency within a population of 180 individuals who were (1) institutionalized (presumably in Portugal) and (2) displayed intellectual/developmental disabilities. The authors measured uric acid and creatinine in urine and plasma, and patients with a high urinary uric acid/creatinine ratio levels (that is, more uric acid than creatinine) or low creatinine levels then underwent an evaluation of urinary and plasma guanidinoacetic acid (GAA). High GAA levels are also suggestive of GAMT deficiency; genetic analyses were also performed. Overall, 4 patients (and a 5th potential patient who had passed away before confirmatory analyses could be done) were identified as having GAMT deficiency, 3 of whom were from one family and the 4th being a third cousin of that family. The 5th patient was unrelated to the first 4 patients. The authors noted that while all patients had relatively normal motor development early in life, they showed a rapid decline in mental capacity in their 2nd year of life. More comprehensive clinical reports on the patients are also provided for the 5 patients.

Link to abstract on PubMed: Guanidinoacetate methyltransferase deficiency identified in adults and a child with mental retardation

ACD Summary: Mustafa et al. analyzed levels of guanidinoacetic acid (GAA), creatine, and creatinine in urine in neurotypical children ages 0- to 15-years-old in Egypt. Specifically, the authors looked at the ratio of GAA to creatinine (GAA:creatinine) and the ratio of creatine to creatinine (creatine:creatinine). Typically, GAA:creatinine levels in urine are low in patients with AGAT deficiency, elevated in patients with GAMT deficiency, and normal in patients with CTD. In contrast, creatine:creatinine levels in urine are normal in patients with AGAT or GAMT deficiency and may be elevated in patients with CTD. These ratios are used by physicians to help with diagnosing CCDS. Accordingly, Mustafa et al. wanted to determine how these ratio levels change with age, so they could begin to establish an age-specific reference level for these diagnostic criteria. The authors collected data on 160 children but removed 10 children from analysis because of positive screening for a CCDS. For the remaining 150 neurotypical children, there was a steady decline in GAA:creatinine and creatine:creatinine levels with age, with there being a large difference in these average levels when comparing children less than 4 years old to children between 4 and 15 years old. Accordingly, the reference criteria for diagnosing CCDS may change with age at time of diagnosis, which may be contributing to the underdiagnosis of CCDS.

Link to free article: Age Adjusted Reference Interval for Creatine Deficiency Syndrome Biomarkers by Gas chromatography-Mass Spectrometry

ACD Summary: Lygate et al. used a mouse model of AGAT deficiency to better understand creatine levels in the liver, kidneys, pancreas, and heart (i.e., the left ventricle). This mouse model of AGAT deficiency is called a AGAT knockout mouse and has a complete deficiency of the AGAT protein. The knockout mice (and normal mice) were fed a diet with creatinine monohydrate, and some mice were also fed a diet that included L-Homoarginine hydrochloride (hArg). AGAT is responsible for producing hArg, so the authors wanted to see how dietary supplemention of creatine monohydrate and/or hArg was associated with creatine levels. (Interestingly, the authors cited recent research indicating that hArg may be involved in cardiovascular health.) In the AGAT knockout mice, supplemention with hArg plus creatine monohydrate led to higher pancreas creatine levels compared to supplementation with only creatine monohydrate. Because hArg and creatine monohydrate seemed to interact with each other to influence creatine levels, the authors concluded that their results have implications for future dietary supplements and therapeutic interventions.

Link to free article: Influence of homoarginine on creatine accumulation and biosynthesis in the mouse

Link to PubMed: PubMed

Scientific Abstract: Creatine deficiency syndromes (CDS) are inherited metabolic disorders caused by mutations in GATM, GAMT and SLC6A8 and mainly affect central nervous system (CNS). AGAT- and GAMT-deficient patients lack the functional brain endogenous creatine (Cr) synthesis pathway but express the Cr transporter SLC6A8 at blood-brain barrier (BBB), and can thus be treated by oral supplementation of high doses of Cr. For Cr transporter deficiency (SLC6A8 deficiency or CTD), current treatment strategies benefit one-third of patients. However, as their phenotype is not completely reversed, and for the other two-thirds of CTD patients, the development of novel more effective therapies is needed. This article aims to review the current knowledge on Cr metabolism and CDS clinical aspects, highlighting their current treatment possibilities and the most recent research perspectives on CDS potential therapeutics designed, in particular, to bring new options for the treatment of CTD.

Link to free article: Current and potential new treatment strategies for creatine deficiency syndromes

Link to PubMed: PubMed

Scientific Abstract: Arginine:glycine amidinotransferase- and guanidinoacetate methyltransferase deficiency are severe neurodevelopmental disorders. It is not known whether mouse models of disease express a neuroanatomical phenotype. High-resolution magnetic resonance imaging (MRI) with advanced image analysis was performed in perfused, fixed mouse brains encapsulated with the skull from male, 10-12 week old Agat -exc and B6J.Cg-Gamt tm1Isb mice (n = 48; n = 8 per genotype, strain). T2-weighted MRI scans were nonlinearly aligned to a 3D atlas of the mouse brain with 62 structures identified. Local differences in brain shape related to genotype were assessed by analysis of deformation fields. Creatine (Cr) and guanidinoacetate (GAA) were measured with high-performance liquid chromatography (HPLC) in brain homogenates (n = 24; n = 4 per genotype, strain) after whole-body perfusion. Cr was decreased in the brain of Agat- and Gamt mutant mice. GAA was decreased in Agat-/- and increased in Gamt-/- . Body weight and brain volume were lower in Agat-/- than in Gamt-/- . The analysis of entire brain structures revealed corpus callosum, internal capsule, fimbria and hypothalamus being different between the genotypes in both strains. Eighteen and fourteen significant peaks (local areas of difference in relative size) were found in Agat- and Gamt mutants, respectively. Comparing Agat-/- with Gamt-/- , we found changes in three brain regions, lateral septum, amygdala, and medulla. Intra-strain differences in four brain structures can be associated with Cr deficiency, while the inter-strain differences in three brain structures of the mutant mice may relate to GAA. Correlating these neuroanatomical findings with gene expression data implies the role of Cr metabolism in the developing brain and the importance of early intervention in patients with Cr deficiency syndromes.

Link to abstract on PubMed: Magnetic resonance imaging reveals specific anatomical changes in the brain of Agat- and Gamt-mice attributed to creatine depletion and guanidinoacetate alteration

Scientific Abstract: Arginine-glycine amidinotransferase (AGAT) deficiency is a rare inherited metabolic disorder that severely affects brain bioenergetics. Characterized by mental retardation, language impairment, and behavioral disorders, AGAT deficiency is a treatable condition, where long-term creatine supplementation usually restores brain creatine levels and improves its clinical features. In some cases of AGAT deficiency, creatine treatment might be somewhat limited due to possible shortcomings in performance and transport of creatine to the brain. Guanidinoacetic acid (GAA), a direct metabolic precursor of creatine, has recently been suggested as a possible alternative to creatine to tackle brain creatine levels in experimental medicine. AGAT patients might benefit from oral GAA due to upgraded bioavailability and convenient utilization of the compound, while possible drawbacks (e.g. brain methylation issues, neurotoxicity, and hyperhomocysteinemia) should be accounted as well.

Link to abstract on PubMed: Benefits and drawbacks of guanidinoacetic acid as a possible treatment to replenish cerebral creatine in AGAT deficiency

ACD Summary: Sharer et al. reported on recommended laboratory methods to diagnose CCDSs. While the authors noted that magnetic resonance spectroscopy (MRS; a noninvasive technique that allows researchers to study the levels of chemical components of the brain’s tissues) can be used, that approach is expensive, requires children to be sedated, and does not specify which CCDS the patient may have. Thus, the authors recommended measuring creatine, guanidinoacetate, and creatinine levels in urine, plasma, or dried blood spots for initial diagnosis. For AGAT or GAMT deficiency, plasma and/or urine can be used; measurements of creatine and guanidinoacetate levels in plasma are specifically recommended. For CTD, urine is the best option. For some female patients with CTD, genetic analyses are also recommended. In general, the authors recommend that the samples be collected when the patients have fasted. The authors also provided a general reference table for relative levels of guanidinoacetate, creatine, and creatine:creatinine ratios in plasma, urine, and cerebrospinal fluid in patients with AGAT deficiency, GAMT deficiency, and CTD. (Cerebrospinal fluid is a fluid that flows through the brain and spinal cord.) The authors did note that creatinine (by itself) has limited value as a diagnostic marker for CCDSs. Additionally, the authors  provided background information on (1) the sources and function of creatine, (2) biochemical/molecular characteristics and clinical descriptions of AGAT, GAMT, and CTD, (3) prevalence and inheritance of CCDSs, and (4) interpretation of test results.

Link to free article: Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics

Link to PubMed: PubMed

ACD Summary: Stocker-Ipsiroglua et al. collected data on 16 patients with AGAT deficiency from their physicians. All the patients were treated with oral creatine monohydrate, starting at ages ranging 4 months old to 25 years old. The goal was to determine how often different clinical characteristics and outcomes were present in those with AGAT deficiency. The most common features of AGAT deficiency were (1) intellectual disability/developmental delay and (2) myopathy (which generally refers to diseases that affect muscles). While creatine-monohydrate treatment was more broadly associated with improved muscle strength across patients of different ages, improved cognitive function was more apparent in those treated at younger ages. In conclusion, given more favorable outcomes in early treated patients, the authors advocated for AGAT newborn screening.

Link to free article: Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide

Link to PubMed: PubMed